Functional gene variants of CYP3A4

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 3, 2014, Pages 340-348

  Werk, A N ^a   Cascorbi, I ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYCLOSPORIN A; CYTOCHROME P450 3A4; ENDOXIFEN; EVEROLIMUS; FENTANYL; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; PROGESTERONE; QUETIAPINE; RAPAMYCIN; SIMVASTATIN; SUNITINIB; TACROLIMUS; TAMOXIFEN; TESTOSTERONE;

AMINO ACID SEQUENCE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; EXON; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; INTRON; LIVER MICROSOME; LOSS OF FUNCTION MUTATION; MULTICENTER STUDY (TOPIC); PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON;

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SAFETY; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84907876975     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.129     Document Type: Review

References (76)

1. Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
2. Ohtsuki, S. et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83-92 (2012).
3. Wang, Z. et al. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: Implications for druginduced osteomalacia. J. Bone Miner. Res. 28, 1101-1116 (2013).
4. Werk, A.N. et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin. Pharmacol. Ther. 95, 416-422 (2014).
5. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
6. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J. & Malkowicz, S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229 (1998).
7. Westlind, A., Löfberg, L., Tindberg, N., Andersson, T.B. & Ingelman-Sundberg, M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205 (1999).
8. Hamzeiy, H., Vahdati-Mashhadian, N., Edwards, H.J. & Goldfarb, P.S. Mutation analysis of the human CYP3A4 gene 5' regulatory region: Population screening using non-radioactive SSCP. Mutat. Res. 500, 103-110 (2002).
9. Fukushima-Uesaka, H. et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100 (2004).
10. T avira, B., Coto, E., Diaz-Corte, C., Alvarez, V., López-Larrea, C. & Ortega, F. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-Transplanted patients. Pharmacogenet. Genomics 23, 445-448 (2013).
11. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011).
12. Elens, L. et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12, 1383-1396 (2011).
13. Elens, L. et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57, 1574-1583 (2011).
14. Elens, L. et al. Impact of CYP3A4 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines. Ther. Drug Monit. 35, 608-616 (2013).
15. Moes, D.J. et al. Effect of CYP3A4 22, CYP3A5 3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst. Pharmacol. 3, e100 (2014).
16. Gijsen, V.M. et al. CYP3A4 22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 14, 1027-1036 (2013).
17. Lunde, I. et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur. J. Clin. Pharmacol. 70, 685-693 (2014).
18. Woillard, J.B., Kamar, N., Coste, S., Rostaing, L., Marquet, P. & Picard, N. Effect of CYP3A4 22, POR 28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. Clin. Chem. 59, 1761-1769 (2013).
19. Baxter, S.D., Teft, W.A., Choi, Y.H., Winquist, E. & Kim, R.B. Tamoxifen-Associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4 22. Breast Cancer Res. Treat. 145, 419-428 (2014).
20. T eft, W.A. et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res. Treat. 139, 95-105 (2013).
21. Diekstra, M.H. et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin. Pharmacol. Ther. 96, 81-89 (2014).
22. Kreutz, R. et al. Cytochrome P450 3A4 22, PPAR-Alpha, and ARNT polymorphisms and clopidogrel response. Clin. Pharmacol. 5, 185-192 (2013).
23. Shi, Y. et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512, 226-231 (2013).
24. Stockmann, C. et al. Fluticasone propionate pharmacogenetics: CYP3A4 22 polymorphism and pediatric asthma control. J. Pediatr. 162, 1222-7, 1227.e1 (2013).
25. Kitzmiller, J.P., Sullivan, D.M., Phelps, M.A., Wang, D. & Sadee, W. CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol. Drug Interact. 28, 59-63 (2013).
26. Elens, L. et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21, 861-866 (2011).
27. Hu, M., Mak, V.W., Xiao, Y. & Tomlinson, B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics 14, 25-34 (2013).
28. García-Martín, E. et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71, 196-204 (2002).
29. Spurdle, A.B. et al. The CYP3A4 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12, 355-366 (2002).
30. Zeigler-Johnson, C. et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64, 8461-8467 (2004).
31. Miao, J. et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9, 319-326 (2009).
32. Gervasini, G., Garcia, M., Macias, R.M., Cubero, J.J., Caravaca, F. & Benitez, J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl. Int. 25, 471-480 (2012).
33. Zochowska, D., Wyzgal, J. & Paczek, L. Impact of CYP3A4 1B and CYP3A5 3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann. Transplant. 17, 36-44 (2012).
34. Murayama, N. et al. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab. Pharmacokinet. 17, 150-156 (2002).
35. Uesugi, M. et al. Influence of cytochrome P450 (CYP) 3A4 1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol. Pharm. Bull. 36, 1814-1821 (2013).
36. Sata, F. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
37. Miyazaki, M., Nakamura, K., Fujita, Y., Guengerich, F.P., Horiuchi, R. & Yamamoto, K. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab. Dispos. 36, 2287-2291 (2008).
38. Garsa, A.A., McLeod, H.L. & Marsh, S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6, 19 (2005).
39. Dai, D. et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
40. Kajinami, K., Brousseau, M.E., Ordovas, J.M. & Schaefer, E.J. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93, 104-107 (2004).
41. Hsieh, K.P. et al. Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273 (2001).
42. Pratt-Hyatt, M., Zhang, H., Snider, N.T. & Hollenberg, P.F. Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide. Drug Metab. Dispos. 38, 2075-2082 (2010).
43. Wang, A. et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60, 843-848 (2005).
44. Eiselt, R. et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458 (2001).
45. Eap, C.B. et al. Pharmacokinetics of midazolam in CYP3A4-And CYP3A5-genotyped subjects. Eur. J. Clin. Pharmacol. 60, 231-236 (2004).
46. Lamba, J.K. et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132 (2002).
47. Nakajima, Y. et al. Impact of the haplotype CYP3A4 16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 80, 179-191 (2006).
48. Shi, X.J., Geng, F., Jiao, Z., Cui, X.Y., Qiu, X.Y. & Zhong, M.K. Association of ABCB1, CYP3A4 18B and CYP3A5 3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: A population pharmacokinetic analysis. J. Clin. Pharm. Ther. 36, 614-624 (2011).
49. Qiu, X.Y. et al. Association of MDR1, CYP3A4 18B, and CYP3A5 3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 64, 1069-1084 (2008).
50. Kang, Y.S. et al. The CYP3A4 18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin. Pharmacol. Ther. 85, 312-318 (2009).
51. Zhou, Q. et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J. Hum. Genet. 56, 415-422 (2011).
52. Drögemöller, B. et al. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front. Genet. 4, 17 (2013).
53. Westlind-Johnsson, A. et al. Identification and characterization of CYP3A4 20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79, 339-349 (2006).
54. Williams, J.A. et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883-891 (2002).
55. T seng, E. et al. Relative contributions of CYP3A4 versus CYP3A5 for CYP3Acleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metabol. Disp. 42, 1163-1173 (2014).
56. Roy, J.N. et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887 (2005).
57. Hustert, E. et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779 (2001).
58. Barraclough, K.A. et al. NR1I2 polymorphisms are related to tacrolimus dose-Adjusted exposure and BK viremia in adult kidney transplantation. Transplantation 94, 1025-1032 (2012).
59. Klein, K. et al. PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91, 1044-1052 (2012).
60. Zhang, J.J., Zhang, H., Ding, X.L., Ma, S. & Miao, L.Y. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur. J. Clin. Pharmacol. 69, 807-812 (2013).
61. Elens, L. et al. Impact of POR 28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther. Drug Monit. 36, 71-79 (2014).
62. Mao, Z. et al. DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes. Biochem. Pharmacol. 84, 701-711 (2012).
63. Dickmann, L.J., Patel, S.K., Wienkers, L.C. & Slatter, J.G. Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr. Drug Metab. 13, 930-937 (2012).
64. McCune, J.S. et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin. Pharmacol. Ther. 68, 356-366 (2000).
65. Pan, Y.Z., Gao, W. & Yu, A.M. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. 37, 2112-2117 (2009).
66. Lamba, V., Ghodke, Y., Guan, W. & Tracy, T.S. microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem. Biophys. Res. Commun. 445, 404-411 (2014).
67. Gonzalez, F.J. et al. Human P450PCN1: Sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79-86 (1988).
68. Barratt, D.T. et al. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet. Genomics 24, 185-194 (2014).
69. Elens, L., Bouamar, R., Hesselink, D.A., Haufroid, V., van Gelder, T. & van Schaik, R.H. The new CYP3A4 intron 6 C
70. Elens, L. et al. CYP3A4 intron 6 C
71. Assis, J. et al. Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: Implication of a CYP3A4 activity profile. Int. J. Clin. Exp. Med. 6, 552-561 (2013).
72. de Graan, A.J. et al. CYP3A4 22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. 19, 3316-3324 (2013).
73. van der Weide, K. & van der Weide, J. The influence of the CYP3A4 22 polymorphism on serum concentration of quetiapine in psychiatric patients. J. Clin. Psychopharmacol. 34, 256-260 (2014).
74. Kurzawski, M., Dabrowska, J., Dziewanowski, K., Domanski, L., Peruzynska, M. & Drozdzik, M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-Adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 15, 179-188 (2014).
75. Shirasaka, Y. et al. Effect of CYP3A5 expression on the inhibition of CYP3Acatalyzed drug metabolism: Impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab. Dispos. 41, 1566-1574 (2013).
76. Willrich, M.A. et al. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clin. Chim. Acta 421, 157-163 (2013).